Alzheimer’s trial to test drug on people without symptoms to see if it can be prevented
Summary
A new international trial is testing a drug called Trontinemab to see if it can prevent Alzheimer’s disease in healthy people who have no memory problems but are at higher risk. The trial is led by the NHS in the UK and will monitor participants for several years to find out if the drug stops dementia before symptoms start.Key Facts
- The trial will recruit about 1,600 people aged 55 to 80 worldwide, including the first European participants in the UK.
- Participants must have no memory loss and will be tested for a blood marker called p-tau217, which indicates risk for Alzheimer’s.
- People with high levels of p-tau217 have a 78% chance of developing cognitive problems within 10 years.
- Trontinemab is a drug made by Roche that targets harmful proteins called amyloid plaques in the brain.
- Early research showed Trontinemab removed amyloid plaques in 90% of people with early Alzheimer’s in 28 weeks.
- Participants will be randomly given either Trontinemab or a placebo and then followed for 4 to 6 years to monitor dementia development.
- The trial involves at least 15 UK hospitals and clinics and focuses on preventing Alzheimer’s before symptoms appear.
- Alzheimer’s disease often develops up to 10 years before memory decline is noticeable, and affects many older adults.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
